Can Animal Models of Disease Reliably Inform Human Studies?

Overview

Journal PLoS Med

Specialty General Medicine

Date 2010 Apr 3

PMID 20361020

Citations 550

Authors

H Bart van der Worp

David W Howells

Emily S Sena

Michelle J Porritt

Sarah Rewell

Victoria OCollins

Malcolm R Macleod

Affiliations

Soon will be listed here.

Abstract

H. Bart van der Worp and colleagues discuss the controversies and possibilities of translating the results of animal experiments into human clinical trials.

Citing Articles

Lipidomics reveals cell specific changes during pluripotent differentiation to neural and mesodermal lineages.

Odenkirk M, Jostes H, Francis K, Baker E Mol Omics. 2025; .

PMID: 40078081 PMC: 11904469. DOI: 10.1039/d4mo00261j.

Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies.

Prego-Dominguez J, Laso-Garcia F, Palomar-Alonso N, Perez-Mato M, Lopez-Arias E, Dopico-Lopez A Pharmaceutics. 2025; 17(2).

PMID: 40006575 PMC: 11859612. DOI: 10.3390/pharmaceutics17020208.

Discordance between preclinical and clinical testing of Na V 1.7-selective inhibitors for pain.

Yang J, Xie Y, Smith R, Ratte S, Prescott S Pain. 2025; 166(3):481-501.

PMID: 39928833 PMC: 11808711. DOI: 10.1097/j.pain.0000000000003425.

Sex-specific effects on the heart from combined exposure to simulated galactic cosmic radiation and hindlimb unloading.

Nemec-Bakk A, Sridharan V, Willey J, Koturbash I, Williams D, Chesal M Life Sci Space Res (Amst). 2025; 44:38-46.

PMID: 39864910 PMC: 11770252. DOI: 10.1016/j.lssr.2024.12.001.

Nanocarrier-mediated cancer therapy with cisplatin: .

Ranasinghe R, Mathai M, Alshawsh M, Zulli A Heliyon. 2025; 10(7):e28171.

PMID: 39839154 PMC: 11747978. DOI: 10.1016/j.heliyon.2024.e28171.

References

Scott S, Kranz J, Cole J, Lincecum J, Thompson K, Kelly N . Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008; 9(1):4-15. DOI: 10.1080/17482960701856300. View

Juni P, Altman D, Egger M . Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323(7303):42-6. PMC: 1120670. DOI: 10.1136/bmj.323.7303.42. View

Sena E, van der Worp H, Howells D, Macleod M . How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci. 2007; 30(9):433-9. DOI: 10.1016/j.tins.2007.06.009. View

Schulz K, Chalmers I, Hayes R, Altman D . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273(5):408-12. DOI: 10.1001/jama.273.5.408. View

Schulz K, Grimes D . Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002; 359(9306):614-8. DOI: 10.1016/S0140-6736(02)07750-4. View

Dirx M, Zeegers M, Dagnelie P, van den Bogaard T, van den Brandt P . Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int J Cancer. 2003; 106(5):766-70. DOI: 10.1002/ijc.11277. View

Dirksen M, Laarman G, Simoons M, Duncker D . Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res. 2007; 74(3):343-55. DOI: 10.1016/j.cardiores.2007.01.014. View

Kimmelman J, London A, Ravina B, Ramsay T, Bernstein M, Fine A . Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations. Mov Disord. 2009; 24(13):1893-901. PMC: 2989599. DOI: 10.1002/mds.22712. View

Gibson C, Gray L, Murphy S, Bath P . Estrogens and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab. 2006; 26(9):1103-13. DOI: 10.1038/sj.jcbfm.9600270. View

10.

Benatar M . Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007; 26(1):1-13. DOI: 10.1016/j.nbd.2006.12.015. View

11.

Banwell V, Sena E, Macleod M . Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis. 2009; 18(4):269-76. DOI: 10.1016/j.jstrokecerebrovasdis.2008.11.009. View

12.

Grotta J . Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2002; 33(1):306-7. View

13.

Festing M, Altman D . Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002; 43(4):244-58. DOI: 10.1093/ilar.43.4.244. View

14.

Besselink M, van Santvoort H, Buskens E, Boermeester M, Goor H, Timmerman H . Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371(9613):651-659. DOI: 10.1016/S0140-6736(08)60207-X. View

15.

Macleod M, OCollins T, Horky L, Howells D, Donnan G . Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005; 25(6):713-21. DOI: 10.1038/sj.jcbfm.9600064. View

16.

Willmot M, Gray L, Gibson C, Murphy S, Bath P . A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide. 2005; 12(3):141-9. DOI: 10.1016/j.niox.2005.01.003. View

17.

Gibson C, Gray L, Bath P, Murphy S . Progesterone for the treatment of experimental brain injury; a systematic review. Brain. 2007; 131(Pt 2):318-28. DOI: 10.1093/brain/awm183. View

18.

Bath P, MacLeod M, Green A . Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke. 2009; 4(6):471-9. DOI: 10.1111/j.1747-4949.2009.00386.x. View

19.

Macleod M, van der Worp H, Sena E, Howells D, Dirnagl U, Donnan G . Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008; 39(10):2824-9. DOI: 10.1161/STROKEAHA.108.515957. View

20.

Bebarta V, Luyten D, Heard K . Emergency medicine animal research: does use of randomization and blinding affect the results?. Acad Emerg Med. 2003; 10(6):684-7. DOI: 10.1111/j.1553-2712.2003.tb00056.x. View